Sidana, Surbhi http://orcid.org/0000-0003-3288-7614
Dispenzieri, Angela
Murray, David L.
Go, Ronald S. http://orcid.org/0000-0002-8284-3495
Buadi, Francis K.
Lacy, Martha Q.
Gonsalves, Wilson I.
Dingli, David
Warsame, Rahma
Kourelis, Taxiarchis
Muchtar, Eli http://orcid.org/0000-0003-2210-2174
Hayman, Suzanne R.
Kapoor, Prashant
Kyle, Robert A.
Leung, Nelson http://orcid.org/0000-0002-5651-1411
Rajkumar, S. Vincent
Gertz, Morie A.
Kumar, Shaji K. http://orcid.org/0000-0001-5392-9284
Funding for this research was provided by:
Amyloidosis Foundation
Article History
Received: 20 June 2019
Revised: 3 November 2019
Accepted: 17 November 2019
First Online: 26 November 2019
Compliance with ethical standards
:
: SS: Honoraria (advisory board), Janssen; AD: Research Funding from Celgene, Takeda, Prothena, Jannsen, Pfizer, Alnylam, GSK; PK: Research Funding from Celgene, Takeda. MQL: Research Funding from Celgene; MAG: Honoraria/consultancy from Ionis, Alnylam, Prothena, Celgene, Janssen, Specytrum, Annexon, Apellis, Amgen, Medscape, Abbvie, Research to Practice, Physcians Education Resource and Teva; SKK: Research Funding and membership on an entity’s Board of Directors or advisory committees: AbbVie, Celgene, Janssen, KITE, Merck. Membership on an entity’s Board of Directors or advisory committees: Oncopeptides, Takeda. Research funding from Novartis and Roche. All potential conflict of interest have been disclosed.